June 10 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O:
MONTE ROSA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER FOR THE TREATMENT OF MULTIPLE INFLAMMATORY DISEASES
MONTE ROSA THERAPEUTICS INC - TO INITIATE PHASE 1 STUDY OF MRT-8102
MONTE ROSA THERAPEUTICS INC - PHASE 1 RESULTS FOR MRT-8102 EXPECTED IN H1 2026
Source text: ID:nGNX7Nxxtr
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))